Spectral Medical Inc. provided an update on the Company's Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion ("PMX") in a randomized controlled trial of adults treated for endotoxemia and septic shock. Enrollment: Robust enrollment activity continuing throughout 2024: 105 patients enrolled at end of April 2024; Record monthly enrollment with seven patients enrolled in April; 24 patients enrolled in 2024 so far - represents the most robust enrollment rates since the start of the Tigris study; With 45 patients to full enrollment, the Company is entering the final push to fully enroll and finish the Tigris trial; To support sustained enrollment, Spectral hosted an in-person Investigator Meeting March 12th & 13th in conjunction with the 29thInternational Conference on Advances in Critical Care Nephrology in San Diego; In-person meeting well attended with multiple stakeholders present, including: principal investigators and clinical research coordinators from existing and new trial sites; CRO, Beaufort; and representatives from the Company's strategic partner Baxter Trial Sites: Continued progress opening additional high quality clinical sites; Recently onboarded the University of Virginia; Two pending sites in the pipeline finalizing contracting and training; Spectral clinical team focused on trial site management activities to ensure that Tigris sites have the support and resources to enroll patients as efficiently as possible.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5 CAD | +2.04% | +1.01% | +17.65% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.65% | 103M | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- EDT Stock
- News Spectral Medical Inc.
- Spectral Medical Inc. Provides Tigris Trial Update